Document is current
Any future updates will be listed below
-
Authors
Zhang, Feng
Zhang, Sun-Han
Liu, Teng
Xie, Guang-Su
Deng, Shi-Hua
Zhang, Ting
Wang, Xiao-Bian
Yang, Yue-Yan
Chen, Zi-Xin
Wu, Dong-Ming
Xu, Ying
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (82273574, 82273433, 82203157)
Foundation of Sichuan Medical Association (S23013, Q21004, S20011)
Chengdu Medical College United Chengdu Seventh People's Hospital Open Subject (2022LHTD-01, 2022LHJYZD-01)
Chengdu Medical College United the First People's Hospital of Ziyang Open Subject (2022LHZY04)
- License Information
-
More Information
Article History
Received: 24 June 2024
Accepted: 20 February 2025
First Online: 7 March 2025
Declarations
:
: The animal study protocol was reviewed and approved by the Animal Policy and Welfare Committee of Chengdu Medical College (CMC-IACUC-2021024; Title: Precision Intervention Strategies for Multiple Diseases with Novel Programmed Cell Death as a Pathogenetic Mechanism; Date of approval: December 31, 2021). The manuscript adhered to the ARRIVE guidelines for the reporting of animal experiments. All animal experiments were carefully performed to avoid animal suffering. The human-derived BEAS-2B has been commercialized and is available for legal purchase under Patent US4885238.
: Not applicable.
: The authors have declared that no competing interest exists.
